Our mission is to better the life conditions of sickle cell disease patients.

We conceive, fabricate, test and sell biomedical apparatus to test the deformability of an heterogeneous population of red blood cells for patients, doctors, researchers and the pharmaceutical industry.

For patients

Point of Care device to monitor the condition on a day-to-day basis.

For doctors

Monitor sickle cell disease patient such as compliance to treatment.

For research

Measure the deformability of red blood cells for various research applications.

For pharma

Faster time to market,
reduced development time & cost of sickle cell disease therapeutics.

EUROBIOMED BIOREZO 22 Février 17h

About sickle cell disease

Learn more about one of the most common genetic blood disorder in the world.

Why red blood cell deformability matters

We provide a new way to test red blood cell deformability, but why is it important ?

About us

ICOVELL creation is the result of fundamental research into the mechanical properties of red blood cells, initiated in 2014 by our team. The structuring elements of the technology developed result from this joint research project, RedPath, funded by Aix Marseille Université’s Initiative d’Excellence (AMIDEX). Since 2014 we have obtained several grants (~€1M, CNRS/AMIDEX/ANR/PhD contracts) that have enabled us to develop the our technology.

Our desire to create a company dates back to 2017. We benefited from mentoring by the Valoritech company, then from the CNRS RISE program and Deeptech Founders (DF) training to formulate and structure the project. This support continues today at the IMPULSE incubator in Marseille, which we joined in early 2021. The history of the project and its major events are shown below.